257 results
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
obligation payable (principally the iOx milestone) and a net decrease in deferred income tax liability.
Operating expenses for the Fiscal 2024 Quarter, which … other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
-current liabilities
Lease liability - non-current
Warrant liabilities
Deferred tax liability
Deferred purchase price payable - Tarus
Deferred … (expense) for income taxes
Income tax benefit (expense)
Net loss
Other comprehensive income (loss)
Net unrealized gain (loss) on investments
Total
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
interest
Total current liabilities
Non-current liabilities
Lease liability - non-current
Warrant liabilities
Deferred tax liability
Deferred purchase … expense
Loss before benefit (expense) for income taxes
Income tax benefit (expense)
Net loss
Other comprehensive income (loss)
Net unrealized gain
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
transaction gain
Interest income, net
Loss before benefit (expense) for income taxes
Income tax benefit (expense)
Net loss
Other comprehensive income (loss … 2023 Quarter, a decrease of $0.8 million, which is discussed more fully below.
Additionally, we reflected a non-cash net deferred income tax benefit
S-8
EX-4.2
PRTG
Portage Biotech Inc
1 Dec 23
Registration of securities for employees
4:05pm
available for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related … of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws;
(ix)
to modify or amend each Award
424B3
9u94ox0j6kv45a 4uo
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.1
qrh m84kn0t
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
6-K
EX-99.1
7eu4g6
28 Nov 23
Current report (foreign)
4:01pm
6-K
EX-99.2
nsd22g9sm5w1uyo
28 Nov 23
Current report (foreign)
4:01pm
424B3
n71d23
7 Nov 23
Prospectus supplement
4:50pm
F-1
uo1ph6syiz ml4
31 Oct 23
Registration statement (foreign)
4:05pm
6-K
EX-4.5
8rtx5xeu1
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.3
xqhrn
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.1
cw4stz
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-10.1
xvq43d unf
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.2
33nnozgjd6q5 xqpx
3 Oct 23
Current report (foreign)
4:05pm
6-K
EX-4.4
lycp02djq43s9vt2c0
3 Oct 23
Current report (foreign)
4:05pm
424B5
iqjww8y9
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
40dxwq4mrl
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
yz9um682
29 Aug 23
Current report (foreign)
4:01pm